Coadministration of pexidartinib (a CYP3A4 inducer) with delicate CYP3A substrates may result in critical therapeutic failures. If concomitant use is unavoidable, boost the CYP3A substrate dosage in accordance with authorized products labeling.Prolonged use during pregnancy may end up in neonatal opioid withdrawal syndrome, which may be life-threat